Reven Pharmaceuticals

10/08/2025

https://www.youtube.com/watch?v=HpU_dDqgLrM

Three leaders from Reven Holdings, Brian Denomme (President/COO), Peter Lange (CEO), and Michael Volk (Chief Strategy & Compliance Officer), join Steve to di...

07/31/2025

Justice for Reven

This isn’t just about a company under attack. It’s about a life-saving breakthrough drug therapy destroyed by bureaucratic overreach. RJX was poised to help millions suffering from sepsis, cardiovascular disease, cancer, and many other chronic and difficult-to-treat, deadly medical conditions - until the SEC stepped in and halted everything. It was done without warning, without a hearing, without charges, and without a trial.
​
We know the facts of the case, it is time everyone else does too!

Track the Reven Pharmaceuticals SEC Legal Case and recent updates at JusticeForReven.com, support Reven and stop SEC Over reach and save RJX

06/14/2023

Reven hits back, opposing SEC’s motion for injunctive relief.

https://reven.com/revens-response-peter-lange-michael-volk-brian-denomme-james-ervin-leah-schaatt-lee-ann-frost/

06/09/2023

Reven among companies expected to boost hypoxia market

The dynamics of the hypoxia market is anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, incremental...

01/08/2023

The Reven team is aware of the recent SEC action against the company and some of its executives. Reven denies the allegations and is working through counsel to respond to them.

09/27/2022

REVEN ANNOUNCES A STRATEGIC LICENSING PARTNERSHIP WITH ENLIGHTENED NUTRACEUTICAL SOLUTIONS, LLC (ENS)

Reven today announced that it has licensed intellectual property, technology and knowledge pertaining to multiple owned patents supported by a decade of pre-clinical and clinical research in anti-inflammatory effects of bio-similar nutrients to ENS

03/16/2022

We have posted our 2021 Annual Year End Recap to our website and Carta.

Dear Shareholders, 2021 is now behind us and we, at Reven, continue to look forward. Despite the pandemic challenges that impacted all aspects of normal business operations, the Reven management team continues to prepare the company for the commercialization of its flagship drug, RJX.

11/05/2021

Reven Holdings Announces the Publication of a Peer-reviewed Article in the Prestigious Medical Journal Frontiers in Oncology

Exciting Medical and Scientific Progress Reported for Reven Holdings’ COVID-19 Drug Candidate

10/22/2021

Reven Announces First Patient Dosed in Double-blind, Randomized, Multi-institutional Phase 2 Clinical Trial Evaluating Its Lead Anti-sepsis Drug Candidate RJX in Hospitalized High-risk COVID-19 Patients

Reven Holdings Announces First Patient Dosed in Double-blind, Randomized, Multi-institutional Phase 2 Clinical Trial Evaluating Its Lead Anti-sepsis Drug Candidate RJX in Hospitalized High-risk COVID-19 Patients October 22, 2021 08:30 AM Eastern Daylight Time WESTMINSTER, Colo.--(BUSINESS WIRE)--Rev...

09/24/2021

Reven Holdings Announces Successful Completion of the First Part of RPI015 Clinical Trial Evaluating Its Lead Anti-sepsis Drug Candidate RJX in Hospitalized High-risk COVID-19 Patients

REVEN SUCCESSFULLY COMPLETES PART 1 OF THE RANDOMIZED COVID-19 STUDY EVALUATING ITS LEAD ANTI-SEPSIS DRUG CANDIDATE RJX

07/09/2021

Reven's Co-Founder Michael Volk Appears on Cheddar News

Reven Holdings, Inc. (“Reven”), a privately held clinical stage biotechnology and pharmaceutical company dedicated to the discovery and development of

07/09/2021

Yesterday, Reven's Co-Founder, Michael Volk sat down with Cheddar News to talk about Reven Pharmaceuticals, RJX, and our clinical trials.

Reven Pharmaceuticals has raised nearly $90 million dollars without venture capital funding. It's flagship product targets multiple bodily systems to keep everything operating in harmony. Michael Volk, Co-Founder, Chief Strategy Officer of Reven Pharmaceuticals, joined Cheddar to discuss.